Observing Queer Stories
This content is for members
ImmunoGen (IMGN)
Why Our Increased Enthusiasm for Incyte’s Product Baricitinib
This content is for members
The STAR of the Week
This content is for members
Prohost Letter #410
This content is for members
ImmunoGen: What About Now?
ImmunoGen is one of two firms Prohost selected for investment on February 2011 based on the promises of its novel antibody-drug conjugate (ADC). An ADC drug is …
Prohost Letter #407
This content is for members
CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY
This content is for members
Prohost Letter #405
This content is for members
Prohost Letter #404 Part 2
This content is for members
Companies Targeted for Takeover Yet Can Thrive on their Own
It seems that the global Takeda (TKPYY) has guessed well what it should pick in order to bring the most effective targeted treatments to cancer patients …
Disrupting the Capability of Cancer Cells to Repair Their Damaged DNA. Underestimated Biotech Firms
This content is for members
Agenus First Immune Check Protein Inhibitor in Clinical Trial. See Also: IMGN and EXEL
This content is for members
Nektar Therapeutics and Seattle Genetics at the AACR Meeting
Meaningful Presentations At the Annual Meeting of the American Association for Cancer Research (AACR) NEKTAR THERAPEUTICS NKTR-214 Drug Improves Survival and …
Prohost Letter #394 Part 2
This content is for members
The Five Prime and Bristol-Myers Squibb Agreement Is Incredible News
This content is for members